COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment

References

• Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–298. doi:10.1038/s41574-019-0176-8
   PubMed Web of Science ®Google Scholar
• Bentham J, Di Cesare M, Bilano V, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–2642. doi:10.1016/S0140-6736(17)32129-3
   PubMed Web of Science ®Google Scholar
• Zupo R, Castellana F, Sardone R, et al. Preliminary trajectories in dietary behaviors during the COVID-19 pandemic: a public health call to action to face obesity. Int J Environ Res Public Health. 2020;17(19):1–15. doi:10.3390/ijerph17197073
   Google Scholar
• Barrea L, Pugliese G, Framondi L, et al. Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index. J Transl Med. 2020;18(1):1–11. doi:10.1186/s12967-020-02465-y
   PubMedGoogle Scholar
• Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. doi:10.1016/j.tim.2016.03.003
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi:10.1016/S0140-6736(20)30251-8
   PubMed Web of Science ®Google Scholar
• Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689–697. doi:10.1016/S0140-6736(20)30260-9
   PubMed Web of Science ®Google Scholar
• Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019- nCoV) infections among travellers from Wuhan, China, 20 28 January 2020. Eurosurveillance. 2020;25(5):1–6. doi:10.2807/1560-7917.ES.2020.25.5.2000062
   Web of Science ®Google Scholar
• Liang M, Gao L, Cheng C, et al. Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis. medRxiv. 2020. doi:10.1101/2020.04.03.20051649
   Google Scholar
• Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973–1987. doi:10.1016/S0140-6736(20)31142-9
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19). Who; 2020.
   Google Scholar
• Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. doi:10.1016/j.tmaid.2020.101623
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• WHO. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. Interim Guid; 2020. Available from: https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117.
   Google Scholar
• Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 2020:200343. doi:10.1148/radiol.2020200343
   PubMed Web of Science ®Google Scholar
• Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368. doi:10.1136/bmj.m606
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020. doi:10.1001/jama.2020.6775
   Web of Science ®Google Scholar
• Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020. doi:10.1002/dmrr.3319
   Google Scholar
• Piva S, Filippini M, Turla F, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 2020;58:29–33. doi:10.1016/j.jcrc.2020.04.004
   PubMed Web of Science ®Google Scholar
• Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 States, March 1 –30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15). doi:10.15585/mmwr.mm6915e3
   Google Scholar
• de Siqueira JVV, Almeida LG, Zica BO, Brum IB, Barceló A, de Siqueira Galil AG. Impact of obesity on hospitalizations and mortality, due to COVID-19: a systematic review. Obes Res Clin Pract. 2020;14(5):398–403. doi:10.1016/j.orcp.2020.07.005
   PubMedGoogle Scholar
• Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: a systematic review. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):655–659. doi:10.1016/j.dsx.2020.05.020
   PubMed Web of Science ®Google Scholar
• Hussain A, Mahawar K, Xia Z, Yang W, S EL-H. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract. 2020;14(4):295–300. doi:10.1016/j.orcp.2020.07.002
   PubMed Web of Science ®Google Scholar
• Barrasa H, Rello J, Tejada S, et al. SARS-Cov-2 in Spanish intensive care: early experience with 15-day survival in Vitoria. Anaesth Crit Care Pain Med. 2020;39(5):553–561. doi:10.1016/j.accpm.2020.04.001
   PubMed Web of Science ®Google Scholar
• Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195–1199. doi:10.1002/oby.22831
   PubMed Web of Science ®Google Scholar
• Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392–1398. doi:10.2337/dc20-0576
   PubMed Web of Science ®Google Scholar
• Hajifathalian K, Kumar S, Newberry C, et al. Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York City. Obesity (Silver Spring). 2020;28(9):1606–1612. doi:10.1002/oby.22923
   PubMedGoogle Scholar
• Zheng KI, Gao F, Wang X-B, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108:154244. doi:10.1016/j.metabol.2020.154244
   PubMed Web of Science ®Google Scholar
• Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and its genetic predisposition with the risk of severe COVID-19: analysis of population-based cohort data. Metabolism. 2020;112:154345. doi:10.1016/j.metabol.2020.154345
   PubMedGoogle Scholar
• Fresán U, Guevara M, Elía F, et al. Independent role of morbid obesity as a risk factor for COVID‐19 hospitalization: a Spanish population‐based cohort study. Obesity. 2020. doi:10.1002/oby.23029
   PubMedGoogle Scholar
• Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer. 2016;7(15):2346–2359. doi:10.7150/jca.16884
   PubMed Web of Science ®Google Scholar
• Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. 2005;69(1):29–35. doi:10.1016/j.diabres.2004.11.007
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR, Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization Find the latest version: obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–184. doi:10.1172/JCI29881.both
   PubMed Web of Science ®Google Scholar
• Zatterale F, Longo M, Naderi J, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2020;10. doi:10.3389/fphys.2019.01607
   PubMed Web of Science ®Google Scholar
• Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Obesity: the “Achilles heel” for COVID-19? Metabolism. 2020;108:8–10. doi:10.1016/j.metabol.2020.154251
   Google Scholar
• Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451–1454. doi:10.1038/s41418-020-0530-3
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998–1002. doi:10.1093/nsr/nwaa041
   PubMed Web of Science ®Google Scholar
• Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762–1769. doi:10.1093/infdis/jiaa150
   PubMed Web of Science ®Google Scholar
• Green WD, Beck MA. Obesity altered T cell metabolism and the response to infection. Curr Opin Immunol. 2017;46:1–7. doi:10.1016/j.coi.2017.03.008
   PubMed Web of Science ®Google Scholar
• Mclaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest. 2017;127(1):5–13. doi:10.1172/JCI88876
   PubMed Web of Science ®Google Scholar
• Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15(8):914–920. doi:10.1038/nm.1964
   PubMed Web of Science ®Google Scholar
• Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy: CD4+ T cells control glucose homeostasis. Nat Med. 2009;15(8):921–929. doi:10.1038/nm.2001.Normalization
   PubMed Web of Science ®Google Scholar
• Tse GMK, To KF, Chan PKS, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol. 2004;57(3):260–265. doi:10.1136/jcp.2003.013276
   PubMed Web of Science ®Google Scholar
• Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte‐like cells in the severity of COVID‐19 infections. Obesity. 2020. doi:10.1002/oby.22856
   PubMedGoogle Scholar
• Rehan VK, Torday JS. The lung alveolar lipofibroblast: an evolutionary strategy against neonatal hyperoxic lung injury. Antioxidants Redox Signal. 2014;21(13):1893–1904. doi:10.1089/ars.2013.5793
   PubMedGoogle Scholar
• El Agha E, Moiseenko A, Kheirollahi V, et al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell. 2017;20(2):261–273.e3. doi:10.1016/j.stem.2016.10.004
   PubMedGoogle Scholar
• Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193–199. doi:10.1007/s00592-009-0109-4
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy. 2005;25(7):963–976. doi:10.1592/phco.2005.25.7.963
   PubMed Web of Science ®Google Scholar
• Mirabelli M, Chiefari E, Puccio L, Foti DP, Brunetti A. Potential benefits and harms of novel antidiabetic drugs during COVID-19 crisis. Int J Environ Res Public Health. 2020;17(10). doi:10.3390/ijerph17103664
   Google Scholar
• Qu H, Zheng Y, Wang Y, et al. The potential effects of clinical antidiabetic agents on SARS-CoV-2. J Diabetes. 2020:1753–0407.13135. doi:10.1111/1753-0407.13135
   Google Scholar
• Chen X, Guo H, Qiu L, Zhang C, Deng Q, Leng Q. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury. Front Immunol. 2020;11:7–12. doi:10.3389/fimmu.2020.02056
   Google Scholar
• Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era? J Diabetes Complications. 2020;34(12): 107723. doi:10.1016/j.jdiacomp.2020.107723
   Google Scholar
• Heaton NS, Randall G. Multifaceted roles for lipids in viral infection. Trends Microbiol. 2011;19(7):368–375. doi:10.1016/j.tim.2011.03.007
   PubMed Web of Science ®Google Scholar
• Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem Biophys Res Commun. 2008;369(2):344–349. doi:10.1016/j.bbrc.2008.02.023
   PubMed Web of Science ®Google Scholar
• Lu JC, Chiang YT, Lin YC, et al. Disruption of lipid raft function increases expression and secretion of monocyte chemoattractant protein-1 in 3T3-L1 adipocytes. PLoS One. 2016;11(12):1–21. doi:10.1371/journal.pone.0169005
   Google Scholar
• Li GM, Li YG, Yamate M, Li SM, Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect. 2007;9(1):96–102. doi:10.1016/j.micinf.2006.10.015
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:1–10. doi:10.1186/1743-422X-2-69
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties. Clin Pharmacokinet. 2020;59(6):659–669. doi:10.1007/s40262-020-00891-1
   PubMedGoogle Scholar
• Wessels I, Maywald M, Rink L. Zinc as a gatekeeper of immune function. Nutrients. 2017;9(12):9–12. doi:10.3390/nu9121286
   PubMedGoogle Scholar
• Gammoh NZ, Rink L. Zinc in infection and inflammation. Nutrients. 2017;9(6). doi:10.3390/nu9060624
   PubMedGoogle Scholar
• De Luis DA, Pacheco D, Izaola O, Terroba MC, Cuellar L, Cabezas G. Micronutrient status in morbidly obese women before bariatric surgery. Surg Obes Relat Dis. 2013;9(2):323–327. doi:10.1016/j.soard.2011.09.015
   PubMedGoogle Scholar
• Suliburska J, Cofta S, Gajewska E, et al. The evaluation of selected serum mineral concentrations and their association with insulin resistance in obese adolescents. Eur Rev Med Pharmacol Sci. 2013;17:2396–2400.
   PubMed Web of Science ®Google Scholar
• Islam MR, Attia J, Ali L, et al. Zinc supplementation for improving glucose handling in pre-diabetes: a double blind randomized placebo controlled pilot study. Diabetes Res Clin Pract. 2016;115:39–46. doi:10.1016/j.diabres.2016.03.010
   PubMed Web of Science ®Google Scholar
• Te Velthuis AJW, van den Worml SHE, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):1–10. doi:10.1371/journal.ppat.1001176
   Google Scholar
• Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ. Chloroquine is a zinc ionophore. PLoS One. 2014;9(10):1–6. doi:10.1371/journal.pone.0109180
   Google Scholar
• Lin MH, Moses DC, Hsieh CH, et al. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res. 2018;150:155–163. doi:10.1016/j.antiviral.2017.12.015
   PubMed Web of Science ®Google Scholar
• Sierra H, Cordova M, Chen CSJ, Rajadhyaksha M. One hormone two actions: anti- and pro-inflammatory effects of glucocorticoids diana. J Invest Dermatol. 2015;135(2):612–615. doi:10.1038/jid.2014.371
   PubMed Web of Science ®Google Scholar
• Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81(1):e13–e20. doi:10.1016/j.jinf.2020.03.062
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020. doi:10.1056/nejmoa2021436
   Google Scholar
• Falzarano D, De Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013;19(10):1313–1317. doi:10.1038/nm.3362
   PubMed Web of Science ®Google Scholar
• Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–1704. doi:10.1016/S0140-6736(20)31042-4
   PubMed Web of Science ®Google Scholar
• Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. doi:10.1016/j.lfs.2020.117477
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/nejmoa2007764
   PubMed Web of Science ®Google Scholar